Press Room

DDL 2025 - Drug Delivery to the Lungs Conference

Start
Wednesday, December 10, 2025
End
Friday, December 12, 2025
Location: Edinburgh, Scotland

Hovione is exhibiting at the Drug Delivery to the Lungs Conference (DDL). In its 36th year, the conference attracts over 1000 attendees worldwide, including scientists, academics, clinicians, regulators and industry experts, and includes a large industry exhibition, a scientific poster hall, expert lectures and excellent networking opportunities over the 3-day event.  

Meet the Hovione team in Edinburgh. 

Speak with our experts and learn more about our complete One-Site Solution that ensures that your inhalation and nasal therapies are engineered for success from start to finish.
 

Schedule a meeting today.

schedule a meeting

 

 

 

More about Inhalation and Nasal at Hovione.

 

 

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025